TVTX - CIK 0001438533
The table below shows Travere Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $78.36M | $110.93M | $75.15M | $61.90M | $36.41M | $32.29M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $87.30M | $82.98M | $38.72M | $34.38M | $25.17M | $24.47M |
| Inventory | $37.05M | $37.55M | $37.68M | $38.01M | $42.88M | $42.98M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $392.68M |
| $371.11M |
| $379.57M |
| $374.17M |
| $324.74M |
| $368.98M |
| Property, plant & equipment | $3.63M | $4.32M | $4.56M | $4.85M | $6.16M | $6.58M |
| Goodwill | - | $800.00K | $800.00K | $800.00K | $800.00K | $800.00K |
| Total assets | $555.19M | $538.58M | $555.31M | $548.80M | $504.41M | $551.12M |
| Accounts payable | $12.91M | $18.23M | $19.13M | $15.37M | $23.20M | $25.84M |
| Total current liabilities | $125.44M | $135.07M | $189.54M | $182.46M | $190.04M | $121.27M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $456.46M | $465.02M | $522.56M | $515.98M | $534.86M | $535.97M |
| Retained earnings | -$1.51B | -$1.48B | -$1.50B | -$1.49B | -$1.39B | -$1.33B |
| Total equity | $98.73M | $73.56M | $32.75M | $32.82M | -$30.45M | $15.15M |